Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular to Raise $800K in Private Financing

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said in a regulatory filing this week that it aims to raise $800,000 through a private offering of stock.

The Tucson, Ariz.-based firm declined to comment on the financing, but in a document filed with the US Securities and Exchange Commission, it said that there are two investors in the round, which comprised an option, warrant, or other right to acquire another security, as well as security to be acquired upon the exercise of an option, warrant, or other right to acquire security.

The investors were not named and HTG Molecular did not say how the proceeds would be used.

The company last week said that it had secured a $16 million debt facility. In February, HTG Molecular said that it initially closed its Series E preferred stock offering for an undisclosed amount.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.